Regeneron’s Gene Therapy Improves Auditory Responses in Children with Genetic Hearing Loss
Regeneron’s trial investigating otoferlin gene therapy (DB-OTO) represents it's first auditory program and is currently enrolling patients.
Regeneron’s trial investigating otoferlin gene therapy (DB-OTO) represents it's first auditory program and is currently enrolling patients.
The research and support in practice by trained hearing health professionals provided the foundation to approve the indication be lowered to 9 months, along with the considerable developments in technology and evolving speech coding strategies in modern day cochlear implant devices.